Summarized by Masters of Longevity from PR Newswire.
Continuous glucose monitoring research for people with type 2 diabetes not using insulin — a primary-care trial preview that highlights potential impacts on everyday glucose management.
Key Takeaways
- Continuous glucose monitors increased daily time in target glucose range by about five hours for noninsulin type 2 diabetes patients.
- Use of continuous glucose monitors reduced hemoglobin A1c by approximately 0.9 percentage points, a clinically meaningful improvement.
- A multicenter randomized trial in primary care settings supports broader CGM use and could inform guideline and coverage expansion.
